Q-omics provides the consensus-scored DTX1 profile across patient tissues and cancer cell-line models. DTX1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DTX1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, DTX1 RNA expression shows 16,997 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where DTX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DTX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DTX1 survival associations across molecular data types. DTX1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DTX1 RNA expression–survival associations across cancer types. High DTX1 expression shows unfavorable associations in KIRC, READ, ACC and BLCA, but favorable associations in ESCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for DTX1 RNA expression.
This table summarizes DTX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DTX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DTX1 shows lower tumor expression in KIRC, KICH, KIRP, HNSC and BRCA and higher tumor expression in STAD. The KIRC box plot shows higher DTX1 RNA expression in normal versus tumor tissue (log2 FC = −2.260, t-test p < 0.001).
This table shows molecular features associated with DTX1 in patient tissues and cancer cell lines. In patient samples, DTX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DTX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
